Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Deal for 100 million doses with additional 100 million through 2023
The company is confident of commencing production at both Mahad and Chiplun units soon
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Subscribe To Our Newsletter & Stay Updated
